Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Increases By 165.9%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 114,600 shares, a growth of 165.9% from the February 28th total of 43,100 shares. Based on an average trading volume of 331,200 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the shares of the company are short sold.

Chugai Pharmaceutical Stock Performance

OTCMKTS:CHGCY traded down $0.25 during mid-day trading on Thursday, reaching $23.31. 82,779 shares of the company’s stock were exchanged, compared to its average volume of 200,398. The firm has a market capitalization of $76.71 billion, a PE ratio of 30.27 and a beta of 0.77. Chugai Pharmaceutical has a one year low of $14.52 and a one year high of $27.19. The business’s fifty day simple moving average is $23.08 and its two-hundred day simple moving average is $22.90.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Thursday, January 30th. The company reported $0.18 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. As a group, equities research analysts forecast that Chugai Pharmaceutical will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.